Effects of 1‐kestose on microbiome changes caused by vonoprazan: a randomized, double‐blind, placebo‐controlled pilot study.

Background and Aim: Potassium‐competitive acid blockers more strongly suppress the gastric acid barrier than proton pump inhibitors and cause dysbiosis. However, preventive measures in this regard have not been established. We aimed to evaluate whether 1‐kestose, a known prebiotic, was effective at alleviating dysbiosis caused by potassium‐competitive acid blockers. Methods: Patients scheduled to undergo endoscopic resection for superficial gastroduodenal tumors were enrolled and randomized 1:1 to receive either 1‐kestose or placebo. All patients were started on potassium‐competitive acid blocker (vonoprazan 20 mg/day) and took 1‐kestose 10 g/day or placebo (maltose) 5 g/day for 8 weeks. The primary outcome was the effect of 1‐kestose on potassium‐competitive acid blocker‐induced alterations in the microbiome. The fecal microbiome was analyzed before and after potassium‐competitive acid blocker treatment via MiSeq (16S rRNA gene V3–V4 region). Results: Forty patients were enrolled, and 16 in each group were analyzed. In the placebo group, the Simpson index, an alpha diversity, was significantly decreased and relative abundance of Streptococcus was significantly increased by 1.9‐fold. In the kestose group, the Simpson index did not change significantly and relative abundance of Streptococcus increased 1.3‐fold, but this was not a significant change. In both groups, no adverse events occurred, ulcers were well healed, and pretreatment and posttreatment short‐chain fatty acid levels did not differ. Conclusions: The potassium‐competitive acid blocker caused dysbiosis in the placebo group; this effect was prevented by 1‐kestose. Thus, 1‐kestose may be useful in dysbiosis treatment. [ABSTRACT FROM AUTHOR]